Table 1 Summary table of the meta-analysis
From: Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis
A) ER | Â | Â | Â | Â | Â | Â | Â | Â |
| Â | Country | Study design | Disease | N | Age (range) | Survival analysis | Hazard ratios | Follow-up, months |
Athanassiadou 1999 [39] | Greece | R | EC | 80 | 62.7 (48–82) | OS | SC | 140 |
Backe 1997 [54] | German | R | EC | 124 | 68 (30–94) | OS | Reported | 57.6 (0.24–180) |
Borazjani 1989 [40] | USA | R | EC | 44 | 66 (36–86) | OS | SC | 120 |
Chambers 1988-1 [51] | USA | R | EC | 168 | – | OS | DE | 24 (1–118.8) |
Covens 2011 [45] | USA | P | EC | 67 | – | OS, PFS | SC | 36 |
Creasman 1985 [13] | USA | R | EC | 168 | 63 (30–92) | DFS | DE | 25 (1–74) |
Engelsen 2008 [34] | Norway | R | EC | 230 | – | OS | SC | 192 |
Felix 2012 [28] | USA | R | EC | 199 | – | OS, RFS | SC | 42 (0.8–144) |
Fukuda 1998 [14] | Japan | R | EEC | 92 | 60.3 (31–86) | DFS, OS | SC, reported | 61.2 (0–174) |
Gates 2006 [52] | USA | R | EC | 108 | 64.2 (27–95) | OS | DE | 60 |
Gonzalez-Rodilla 2013 [20] | Spain | R | EC | 126 | 65.9 (43–88) | OS | Report | 70 |
Gul 2010 [31] | Turkey | R | EC | 49 | 58.3 (30–81) | OS | DE | 24 |
Huvila 2013 [61] | Finland | R | EEC | 182 | 67 (35–93) | DFS | Reported | 62.8 (4.2–84.4) |
Ito 2005 [57] | Japan | R | EEC | 103 | 57 | OS | Reported | 60 (2–148) |
Jongen 2009 [17] | Netherlands | R | EEC | 315 | 64.7 (32–89) | DSS, RFS, OS | SC | 59.6 (0–258) |
Kadar 1993 [16] | USA | R | EC | 137 | – | OS | DE | 60 |
Kamat 2009 [32] | USA | R | EEC | 139 | 63 (27–91) | DSS | Reported | 24.9 |
Kalogiannidis 2008 [35] | Greece | R | EC | 77 | 62.5 (35–80) | OS, CSS, DFS | DE | 60 (9–120) |
Kauppila 1986 [42] | Finland | R | EC | 153 | – | DFS, OS | SC | 42 (12–96) |
Krakstad 2012-primary [27] | Norway | P | EC | 182 | – | DSS | SC | 60 |
Krakstad 2012-prospective [27] | Norway | P | EC | 474 | – | DSS | SC | 60 |
Lenhard 2013 [59] | German | P | EC | 292 | 65.1 (35.6–88) | OS | Reported | 13.8 (13.1–14.5) |
Liao 1986 [43] | USA | R | EC | 75 | – | OS | SC | 50 |
Lindahl 1992 [50] | Sweden | R | EC | 298 | 63 (36–87) | OS | DE | 60 |
Martin 1983 [44] | Australia | P | EC | 87 | (48–85) | OS | SC | (8–68) |
Merritt 2010 [55] | USA | R | EEC | 85 | 63.4 (39–91) | DSS | Reported | 72 |
Mhawech-Fauceglia 2013 [48] | USA | R | EC | 316 | – | OS | DE | 60 |
Mylonas 2010 [30] | Germany | R | EEC | 214 | 65.1 (35–88) | PFS, CSS, OS | SC | 96.3 (0.03–176.8) |
Palmer 1988 [41] | Australia | R | EC | 351 | 64.5 (31–89) | OS | SC | 100 |
Pertschuk 1996 [47] | Caucasian, Hispanic, Oriental | R | EC | 78 | 65.5 (38–89) | OS | SC | 37.5 (13–161) |
Pradhan 2012 [26] | Norwegian | P | UPSC | 52 | 72 (56–89) | OS, PFS | DE | 60 |
Saito 2006 [56] | Japan | R | EEC | 103 | 57 | DFS, OS | Reported | 60 (2–148) |
Rahman 2013 [18] | Japan | R | EEC | 111 | 60 (26–85) | PFS, OS | Reported | 52 (5–139) |
Salvesen 1998 [58] | Norway | P | EC | 97 | 65 (37–92) | OS | DE | 108 (60–180) |
Shabani 2007 [36] | Germany | R | EC | 293 | 64.8 (35.5–88) | PFS, CSS, OS | SC | 89.6 (3.2–135.5) |
Sho 2014 [60] | Japan | R | UPSC | 33 | 69.6 (55–82) | CSS | Reported | 29 (2–174) |
Singh 2007 [37] | USA | P | EC | 48 | – | OS | Reported | 19 |
Sivridis 2001 [38] | Greece | R | EC | 164 | – | OS | SC | 55 (19–167) |
Song 2012 [29] | Korea | R | EC | 137 | 53.7 (30–82) | OS | Reported | 60 |
Sun 2013 [46] | China | P | EC | 73 | 58 (30–78) | DFS | SC | 43.4 (16–91) |
Voss 2011 [22] | England | P | EC | 156 | 68.2 (37–89) | DSS, RFS | Reported | 48.1 (0.1–141.5) |
Wik 2013-R [49] | Norway | R | EC | 266 | – | DSS | SC | 300 |
Wik 2013-P [49] | Norway | P | EC | 153 | – | DSS | SC | 300 |
Zannoni 2013 [25] | Italy | P | EEA | 121 | 59 (35–88) | DFS, OS | Reported | 38 (14–91) |
Zhang 2013 [53] | China | R | EC | 239 | 54 (26–82) | DFS, OS | DE | 67 (12–183) |
Zou 2012 [21] | China | R | EEC | 60 | 51.3 (30–72) | OS | Reported | 45.5 (3–69.5) |
B) PR | Â | Â | Â | Â | Â | Â | Â | Â |
| Â | Country | Study design | Disease | N | Age (range) | Survival analysis | Hazard ratios | Follow-up, months |
Athanassiadou 1999 [39] | Greece | R | EC | 80 | 62.7 (48–82) | OS | SC | 140 |
Backe 1997 [54] | German | R | EC | 197 | 68 (30–94) | OS | Reported | 57.6 (0.2–180) |
Borazjani 1989 [40] | USA | R | EC | 44 | 66 (36–86) | OS | SC | 120 |
Chambers 1988-1 [51] | USA | R | EC | 168 | 67 (49–90) | OS | DE | 24 (1–118.8) |
Creasman 1985 [13] | USA | R | EC | 105 | 63 (30–92) | DFS | DE | 25 (1–74) |
Ehrlich 1988 [65] | USA | R | EC | 174 | 56 (25–89) | OS | SC | 27 (1–152) |
Engelsen 2008 [34] | Norway | R | EC | 230 | – | OS | Reported | 192 |
Fukuda 1998 [14] | Japan | R | EEC | 92 | 60.3 (31–86) | DFS | SC | 61.2 (0–174) |
Gates 2006 [52] | USA | R | EC | 108 | 64.2 (27–95) | OS | Report | 60 |
Gonzalez-Rodilla 2013 [20] | Spain | R | EC | 126 | 65.9 (43–88) | OS | Reported | 70 |
Gul 2010 [31] | Turkey | R | EC | 49 | 58.3 (30–81) | OS | DE | 24 |
Huvila 2013 [61] | Finland | R | EEC | 182 | 67 (35–93) | DFS | Reported | 62.8 (4.2–84.4) |
Ito 2005 [57] | Japan | R | EEC | 103 | 57 | DFS, OS | Reported | 60 (2–148) |
Jongen 2009 [17] | Netherlands | R | EEC | 300 | 64.7 (32.0–89.0) | DSS, RFS, OS | SC, reported | 59.6 (0–258) |
Kadar 1993 [16] | USA | R | EC | 137 | – | OS | DE | 60 |
Kalogiannidis 2008 [35] | Greece | R | EC | 77 | 62.5 (35–80) | OS, CSS, DFS | DE | 60 (9–120) |
Kamat 2009 [32] | USA | R | EEC | 139 | 63 (27–91) | DSS | report | 24.9 |
Kauppila 1986 [42] | Finland | R | EC | 153 | – | DFS, OS | SC | 42 (12–96) |
Liao 1986 [43] | USA | R | EC | 86 | Â | OS | SC | 50 |
Lenhard 2013 [59] | German | P | EC | 292 | 65.1 (35.6–88.1) | OS | Reported | 13.8 (13.1–14.5) |
Lindahl 1992 [50] | Sweden | R | EC | 272 | 63 (36–87) | OS | DE | 60 |
Merritt 2010 [55] | USA | R | EEC | 85 | 63.4 (39–91) | DSS | Reported | 72 |
Palmer 1988 [41] | Australia | R | EC | 351 | 64.5 (31–89) | OS | SC | 100 |
Pradhan 2012 [26] | Norwegian | P | SAC | 50 | 72 (56–89) | OS, PFS | DE | 60 |
Rahman 2013 [18] | Japanese | R | EEC | 110 | 60 (26–85) | PFS, OS | Reported | 52 (5–139) |
Sakaguchi 2004 [62] | Japan | R | EC | 120 | 32–74 | OS | SC | 60 |
Saito 2006 [56] | Japan | P | EEC | 103 | 57 | DFS, OS | Reported | 60 (2–148) |
Salvesen 1998 [58] | Norway | P | EC | 96 | 65 (37–92) | OS | Reported | 108 (60–180) |
Shabani 2007 [36] | Germany | R | EC | 293 | 64.8 (35.5–87.9) | PFS, CSS, OS | SC | 89.6 (3.2–135.5) |
Singh 2007 [37] | USA | P | EC | 49 | Â | OS | Reported | 19 |
Sivridis 2001 [38] | Greece | R | EC | 164 | – | OS | SC | 55 (19–167) |
Song 2012 [29] | Korea | R | EC | 137 | 53.7 (30–82) | OS | Reported | 60 |
Steiner 2003 [63] | Germany | R | EC | 115 | 65 (38–81) | OS, RFS | SC | 72 (36–156) |
Sutton 1989 [64] | USA | R | EC | 139 | 61 (31–89) | DFS | SC, DE | 28.9 (1–128) |
Voss 2011 [22] | England | P | EC | 156 | 68.2 (37–89) | DSS, RFS | Reported | 48.1 (0.1–141.5) |
Zannoni 2013 [25] | Italy | P | EEC | 121 | 59 (35–88) | DFS, OS | Reported | 38 (14–91) |
Zhang 2013 [53] | China | R | EC | 239 | 54 (26–82) | DFS, OS, RFS | SC | 67 (12–183) |
Zou 2012 [21] | China | R | EEC | 60 | 51.3 (30–72) | OS | Reported | 45.5 (3–69.5) |
C) HER2 | Â | Â | Â | Â | Â | Â | Â | Â |
| Â | Country | Study design | Disease | N | Age (range) | Survival analysis | Hazard ratios | Follow-up, months |
Backe 1997 [54] | German | R | EC | 222 | 68 (30–94) | OS, RFS | SC | 57.6 (0.24–180) |
Cianciulli 2003 [76] | Italy | R | EC | 73 | Â | OS | SC | 72 |
Coronado 2001 [72] | Spain | R | EC | 114 | 65 (37–85) | PFS | SC | 6 (14–107) |
Gates 2006 [52] | USA | R | EC | 99 | 64.2 (27–95) | OS | report | 60 |
Gonzalez-Rodilla 2013 [20] | Spain | R | EC | 126 | 65.9 (43–88) | OS | report | 70 |
Jongen 2009-2 [33] | Netherlands | P | EEC | 315 | 64.7 (32–89) | OS, RFS | Reported | 59.6 (0–258) |
Kohlberger 1996 [73] | Australia | R | EC | 100 | 64 (36–85) | OS | SC | 140 |
Konecny 2009 [68] | USA | R | EC | 273 | 65 (38–90) | OS | SC | EEA83 (0.3–270) USPC20 (0.1–162), CCC38 (0.2–180) |
Mori 2010 [67] | Japan | R | EEC | 63 | 57.5 (32–78) | RFS, OS | SC | 61.9 (7–133) |
Odicino 2008 [69] | Italy | R | USPC | 10 | positive: 79–84; negative: 57–76 | OS | DE | 19.7 (1–87) |
Peiro 2004 [76] | German | R | EC | 10 | 60 (29–91) | OS | SC, reported | 53 |
Saffari 1995 [74] | Hispanic | R | EC | 75 | 60 (29–87) | OS | SC | 144 |
Santin 2005-1 [70] | USA | R | USPC | 27 | 66 (62–75) | DSS, OS | SC, reported | 33 (10–48) |
Santin 2005-2 [71] | USA | R | USPC | 30 | 67.5 (63–75) | OS | SC | 42 (10–51) |
Togami 2012 [66] | Japan | R | UPSC | 71 | 63.6 (47–81) | RFS, OS | Reported | 49.7 (4–125) |
Voss 2011 [22] | England | P | EC | 156 | 68.2 (37–89) | DSS, RFS | Reported | 48.12 (0.12–141.48) |